Vaginal Atrophy following Long-Term Depot Medroxyprogesterone Acetate Use: A Case Report | Zendy

Christie L. Walker | Zendy; Shawky Z.A. Badawy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vaginal Atrophy following Long-Term Depot Medroxyprogesterone Acetate Use: A Case Report

Author(s) -

Christie L. Walker,

Shawky Z.A. Badawy

Publication year - 2013

Publication title -

case reports in obstetrics and gynecology

Language(s) - English

Resource type - Journals

eISSN - 2090-6684

pISSN - 2090-6692

DOI - 10.1155/2013/835316

Subject(s) - medicine , medroxyprogesterone acetate , hypoestrogenism , vaginal cytology , vaginal atrophy , introitus , vagina , ovulation , medroxyprogesterone , gynecology , atrophy , menopause , surgery , hormone , endocrinology , estrous cycle

Depot medroxyprogesterone acetate (DMPA) is a commonly used form of contraception, with noncontraceptive benefits for the user. The mode of action is through the suppression of ovulation. It leads to hypoestrogenism which causes dryness of the vagina and dyspareunia. We present in this paper a patient that was very symptomatic with regard to vaginal atrophic changes determined by vaginal cytology. This side effect may become increasingly more common as we see more long-term use of DMPA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research